Lenalidomide
191732-72-6
Shanghai Port
1kg;10kg
2023-08-05
Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceYellow SolidChEBI: A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha.Lenalidomide is a derivative of thalidomide differing in the presence of an amino moiety in the 4-position and removal of one of the carbonyls of the phthaloyl ring. While other indications are under evaluation, lenalidomide has initially been launched for the treatment of myelodysplastic syndro
Solid
Lenalidomide is a dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha. It has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. It is a member of isoindoles, a dicarboximide, a member of piperidones and an aromatic amine.|Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. FDA approved on December 27, 2005.|Pomalidomide is an immunomodulatory and antineoplastic agent that is used in the therapy of multiple myeloma. Pomalidomide, like the structurally related agents thalidomide and lenalidomide, is associated with a low rate of serum aminotransferase elevations during therapy and has been implicated in causing rare instances of clinically apparent liver injury which can be severe.|Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.|A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.Basic Info-
Product Name:
Lenalidomide
Other Name:2,6-Piperidinedione,3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione;3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione;Revimid;CC 5013;CDC 501;Lenalidomide;Revlimid;1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole;3-(4-Amino-1-oxoisoindolin-2-yl)piperidin-2,6-dione;ENMD 0997;IMiD 3;revlMiD;346670-73-3;443912-14-9;824975-68-0
CAS No.:191732-72-6
Molecular Formula:C13H13N3O3
InChIKeys:InChIKey=GOTYRUGSSMKFNF-UHFFFAOYSA-N
Molecular Weight:259.26062
Exact Mass:259.26
EC Number:1308068-626-2
NSC Number:747972
DSSTox ID:DTXSID8046664
Color/Form:Off-white to pale-yellow solid powder
ATC Code:L04AX04|L04AX|L - Antineoplastic and immunomodulating agents
HScode:29339900
Categories:
Characteristics-
PSA:
92.5
XLogP3:-0.5
Appearance:Solid
Density:1.460±0.06 g/cm3(Predicted)
Melting Point:269-271°C
Boiling Point:614.0±55.0 °C(Predicted)
Flash Point:325.1±31.5 °C
Refractive Index:1.672
Water Solubility:soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.
Storage Conditions:-20°C Freezer
Vapor Pressure:1.78X10-13 mm Hg at 25 deg C (est)
Specific rotation:Has an asymmetric carbon atom and can exist as the optically active forms S(-) and R(+), and is produced as a reacemic mixture with a net optical rotation of zero
Henrys Law Constant:Henry's law constant = 1.26X10-17 atm-cu m/mol at 25 °C (est)
Dissociation Constants:pKa1 = 2.31 (primary amine); pKa2 = 11.61 (secondary amine) (est)
Hazard IdentificationClassification of the substance or mixture
Reproductive toxicity, Category 1B
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H360 May damage fertility or the unborn child
H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P318 IF exposed or concerned, get medical advice.
P319 Get medical help if you feel unwell.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine
-
Location:
Honggutan District, Nanchang City, Jiangxi Province
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
50
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2021
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product